Mammary Cell News Volume 11.10 | Mar 21 2019

TOP STORY

Multiple ABCB1 Transcriptional Fusions in Drug Resistant High-Grade Serous Ovarian and Breast Cancer

Researchers reported that ovarian and breast samples from chemotherapy treated patients were positive for multiple transcriptional fusions involving ABCB1, placing it under the control of a strong promoter while leaving its open reading frame intact. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Dual Complementary Liposomes Inhibit Triple-Negative Breast Tumor Progression and Metastasis

Investigators screened a panel of cancer cell surface markers and identified intercellular adhesion molecule-1 and epithelial growth factor receptor as optimal candidates for triple-negative breast cancer complementary targeting. [Sci Adv] Full Article | Press Release

p27 Transcriptionally Coregulates cJun to Drive Programs of Tumor Progression

In breast and bladder cancer cells with high p27pT157pT198 or expressing a CDK-binding defective p27pT157pT198 phosphomimetic, cJun was activated and interacted with p27, and p27/cJun complexes localized to the nucleus. [Proc Natl Acad Sci USA] Full Article

Long Non-Coding RNA NEAT1 Confers Oncogenic Role in Triple-Negative Breast Cancer through Modulating Chemoresistance and Cancer Stemness

Among 90 long non-coding RNAs, nuclear paraspeckle assembly transcript 1 (NEAT1) was highly expressed in the blood samples of breast cancer patients than in normal controls. In particular, the expression of NEAT1 was higher in triple-negative breast cancer tissues than other subgroups. [Cell Death Dis] Full Article

Modeling Differentiation-State Transitions Linked to Therapeutic Escape in Triple-Negative Breast Cancer

The authors developed computational models of a drug-treated, phenotypically heterogeneous triple-negative breast cancer cell line to elucidate the feasibility of differentiation-state transition as a mechanism for therapeutic escape in this tumor subtype. [PLoS Comput Biol] Full Article

Cortisol-Induced SRSF3 Expression Promotes GR Splicing, RACK1 Expression and Breast Cancer Cells Migration

Scientists provided the first evidence that glucocorticoid receptor (GR) α transcriptionally regulated receptor for activated C kinase 1 (RACK1) by a mechanism connected to SRSF3 splicing factor, which promotes GRα, essential for RACK1 transcriptional regulation and consequently for cells migration. [Pharmacol Res] Abstract | Graphical Abstract

Sensitization and Synergistic Anti-Cancer Effects of Furanodiene Identified in Zebrafish Models

Furanodiene showed a markedly synergistic anti-cancer effect when used in combination with 5-fluorouracil for both human breast cancer MDA-MB-231 cells and human liver cancer BEL-7402 cells xenotransplanted into zebrafish. [Sci Rep] Full Article

Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly

Researchers used triple negative breast cancer-derived MDA-MB231 and MDA-MB453 cells that, albeit at different extent, both expressed androgen receptor (AR). Androgen challenging induced migration and invasiveness of these cells. [Sci Rep] Full Article

Myoglobin Induces Mitochondrial Fusion Thereby Inhibiting Breast Cancer Cell Proliferation

Scientists demonstrated in vitro that expression of human myoglobin in MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cells induced mitochondrial hyperfusion by up-regulating mitofusins 1 and 2, the predominant catalysts of mitochondrial fusion. [J Biol Chem] Abstract | Full Article

Baicalein Suppresses Stem Cell-Like Characteristics in Radio- and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2

Baicalein sensitized radio- and chemoresistant cells and induced apoptosis, while suppressing stem cell-like characteristics, such as mammosphere formation, side population, expression of Oct3/4 and ABCG2, and CD44^highCD24^low population in MDA-MB-231/IR cells. [Nutrients] Full Article | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

Higher Order Genomic Organization and Epigenetic Control Maintain Cellular Identity and Prevent Breast Cancer

The authors present a strategic overview of epigenetic regulatory mechanisms including histone modifications and higher order chromatin organization that are perturbed in breast cancer onset and progression. [Genes Chromosomes Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

LAM To Present Data for Cell-Free DNA Methylation Assay for Non-Invasive Diagnosis of Liver, Breast and Colorectal Cancers

Laboratory for Advanced Medicine announced a poster presentation titled “Circulating Cell-Free DNA Methylation Assay: Towards Early Detection of Multiple Cancer Types” will be presented. [Press release from the Laboratory for Advanced Medicine (PR Newswire Association LLC) discussing research to be presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, Atlanta] Press Release

Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

Adlai Nortye Ltd. announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global Phase III clinical trial for pelareorep in combination with paclitaxel in patients with advanced/metastatic breast cancer in China. [Adlai Nortye Ltd. (PR Newswire Association LLC)] Press Release

Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial

Modra Pharmaceuticals B.V. announced that the first patients have been treated in its Phase IIa study in patients with recurrent or metastatic HER-2 negative breast cancer. [Modra Pharmaceuticals B.V. (Business Wire)] Press Release

Zenith Epigenetics Announces US FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program

Zenith Epigenetics Ltd. announced that the FDA has cleared the company’s investigational new drug application for ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor, for triple negative breast cancer (TNBC) in combination with talazoparib, a poly ADP ribose polymerase inhibitor. [Zenith Capital Corp.] Press Release

Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX^® (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. announced that its licensing partner Specialised Therapeutics Asia has received marketing authorization from Australia’s Therapeutic Goods Administration to commercialize neratinib in Australia for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab based therapy. [Puma Biotechnology, Inc.] Press Release

NEW Keystone Symposia: Tumor Metabolism
March 8-12, 2020
Banff, Alberta, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Breast Cell Atlas (University of Cambridge)

Professor – Breast Cancer (University Hospitals Cleveland Medical Center)

Postdoctoral Researcher – BRCA1/2-Deficient Tumors (University of Oxford)

Postdoctoral Scientist – Breast Tumor Suppressor BRCA1 in DNA Repair (The George Washington University)

Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory)

Scientific Review Officer – Breast Cancer (METAvivor)

Faculty Position – Breast Cancer Research (The Mayo Clinic)

Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA)

Postdoctoral Fellowship – Breast Cancer (Providence John Wayne Cancer Institute)

Postdoctoral Fellow – Breast Cancer Research (City of Hope)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.